CANbridge Pharmaceuticals
Manufacturing · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Suzhou Industrial Park Building 21 Xinpi...Phone Number
+86 1084148018Website
www.canbridgepharma.comRevenue
$13.2 MillionStock Symbol
1228Industry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About CANbridge Pharmaceuticals
CANbridge is a global biopharmaceutical company founded in 2012, focused on developing and delivering innovative therapeutics for rare diseases and rare oncology. The company bridges the gap between effective therapeutic products from around the world and the rapidly expanding Chinese market. Their product portfolio includes approved therapies such as Gaurunning, Livmarli, and Hunterase, aimed at addressing unmet medical needs. CANbridge targets clients in the rare disease community, leveraging gene therapy to create impactful solutions for patients with rare genetic conditions.Explore more
CANbridge Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CANbridge Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if CANbridge Pharmaceuticals had a recent Job posting/layoffs
Check out if CANbridge Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when CANbridge Pharmaceuticals launches new products
CANbridge Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if CANbridge Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once CANbridge Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at CANbridge Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on CANbridge Pharmaceuticals recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined CANbridge Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to CANbridge Pharmaceuticals
Compare insights from companies similar to CANbridge Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CANbridge Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CANbridge Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CANbridge Pharmaceuticals.
CANbridge Pharmaceuticals financials insights
Gather financial insights about CANbridge Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$10M
2017
Series B
$25M
2018
Series C
$38.1M
2020
Series D
$98M
Series E
$43M
CANbridge Pharmaceuticals Tech Stack
A closer look at the technologies used by CANbridge Pharmaceuticals
See more technologies
Most Recent Scoops
New Hire
Executive Move
Event
Events
Executive Move
Board of Directors
Executive Move
Board of Directors
New Hire
Executive Move
CANbridge Pharmaceuticals News & Media
CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress
BEIJING and CAMBRIDGE, Mass., Oct. 25, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals, Inc. ("CANbridge," stock code 1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare...CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration
BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies,...CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China
BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare disease and rare oncology, announced that the core part of the ongoing CAN103 Phase 2 trial, in treatment-naïve patients aged 12 or above with Gaucher disease (GD) Types I and III, has reached full enrollment. Phase 2 is a randomiCANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)
LIVMARLI is the First and Only Treatment Approved in Taiwan for Cholestatic Pruritus in ALGS LIVMARLI is approved for Cholestatic Pruritus in ALGS in the US, Canada, Europe, Mainland China, and other regions globally BEIJING and BURLINGTON, Mass., Oct. 9, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and o
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CANbridge Pharmaceuticals
Sign Up For FreeTo access detailed company insights
CANbridge is a global biopharmaceutical company founded in 2012, focused on developing and delivering innovative therapeutics for rare diseases and rare oncology. The company bridges the gap between effective therapeutic products from around the world and the rapidly expanding Chinese market. Their product portfolio includes approved therapies such... Read More
